Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases
NCT00437957 is a phase 1 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. As of 21 Nov 2026, it was terminated. It studies Temozolomide and Valproate in Brain Metastases. The registry lists an enrollment of 10 participants at 1 site in 1 country. The registry lists a start date of 31 Dec 2006 and a primary completion date of 30 Apr 2009. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT00437957 |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Enrollment | 10 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Brain Metastases |
| Drugs | Temozolomide and Valproate |
| Start | 31 Dec 2006 |
| Primary completion | 30 Apr 2009 |
| Study completion | 30 Apr 2009 |
| Last update posted | 23 Feb 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Jade Homsi, MD
H. Lee Moffitt Cancer Center and Research Institute
Principal InvestigatorKOL profile → - Sajeel Chowdhary, MD
H. Lee Moffitt Cancer Center and Research Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- H. Lee Moffitt Cancer Center & Research Institute
Tampa
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT00437957
Each answer restates registry values shown on this page.
What is NCT00437957?
NCT00437957 is a phase 1 interventional trial sponsored by H. Lee Moffitt Cancer Center and Research Institute. It studies Temozolomide and Valproate in Brain Metastases.
Who leads NCT00437957?
The registry names Jade Homsi, MD (principal investigator, H. Lee Moffitt Cancer Center and Research Institute) and Sajeel Chowdhary, MD (principal investigator, H. Lee Moffitt Cancer Center and Research Institute) as overall officials.
Where does NCT00437957 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT00437957 study?
The registered drug and biological interventions are Temozolomide and Valproate.
When did NCT00437957 end?
The registry lists a primary completion date of 30 Apr 2009 and a study completion date of 30 Apr 2009. The sponsor last updated the record on 23 Feb 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.